Liver cancer

Liver cancer worldwide is shifting from being mainly caused by hepatitis B infection and food toxins (aflatoxin) toward being driven more by metabolic conditions (fatty liver disease linked to obesity, called MASH) and alcohol use, and this shift varies sharply by region and wealth level. At the same time, rare inherited disorders called porphyrias, which disrupt the body's blood-pigment production, are being recognized as another under-the-radar risk factor requiring liver specialists' attention.

Liver cancer (hepatocellular carcinoma, or HCC) increasingly looks like the result of three connected processes working together: leaky-gut bacteria triggering liver inflammation, immune cells in the liver switching into cancer-promoting modes, and platelets (blood-clotting cells) influencing scarring (fibrosis) of the liver; together these push chronic liver disease toward cancer rather than acting as separate risk factors.

Researchers are using single-cell and spatial technologies (tools that examine one cell at a time rather than blending tissue together) to map exactly how liver cancer cells team up with surrounding support cells to hide from the immune system, and are using these insights to design combination treatments and blood/tissue-based tests to detect and reverse that hiding.

Researchers are studying plant-derived and traditional-medicine compounds that fight liver cancer by triggering cell death, blocking the changes that let tumor cells spread, and using the body's own stress and immune responses, while a separate but related thread looks at how genetic 'switches' controlling cell metabolism make liver cancer more aggressive.

Liver cancer cells resist standard drugs (sorafenib, lenvatinib) partly by shutting down 'ferroptosis'—a form of cell death triggered by iron and oxidative damage to fats in cell membranes—and researchers are finding several distinct ways to force this death pathway back on, which restores drug sensitivity in lab models.

Fatty liver disease linked to obesity and diabetes (MASLD) is projected to keep rising sharply, especially among young people, while diabetes drugs like semaglutide and tirzepatide are emerging as effective treatments because the condition is increasingly understood as a whole-body metabolic problem, not just a liver problem.

Researchers are combining local tumor-destroying treatments (like ultrasound-activated nanoparticles, blood-vessel blocking, and heat ablation) with drugs that unleash the immune system against liver cancer, while also exploring natural compounds and personal biological markers (like genes and sex) to better match treatments to patients.

Because the liver is a common site for cancer to spread (from colorectal, pancreatic, and lung cancers) and naturally suppresses immune attacks on tumors, researchers are converging on two fronts: catching cancer earlier with blood tests instead of scans or biopsies, and re-activating the immune system directly inside the liver to fight tumors, with a new lab technique that keeps whole diseased livers alive outside the body to test both approaches realistically.